May 20, 2013 (Shareholders Foundation) - An investigation on behalf of current investors, who purchased their NYSE:BCR shares as early as 1998 or earlier, was announced concerning whether certain officers and directors of C.R. Bard, Inc. potentially breached their fiduciary duties.

The investigation by a law firm concerns whether certain C.R. Bard officers and directors breached their fiduciary duties and caused damage to the company and its shareholders by, among other things, failing to implement adequate internal controls.

In November 2006, C.R. Bard, Inc. received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the companys brachytherapy business. On January 27, 2012, C.R. Bard, Inc. announced that it had reached a preliminary agreement with the civil and criminal divisions of the United States Attorneys Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter.

C.R. Bard, Inc. reported that its annual Total Revenue rose from over $2.53 billion in 2009 to over $2.95 billion in 2012 and its respective Net Income increased from $460.10 million to $530.10 million.

Shares of C.R. Bard, Inc. (NYSE:BCR) grew from slightly under $71 per share in May 2009 to as high as almost $113 in July 2011 but fell in the second half of 2011 to almost $83 per share.

On May 20, 2013, NYSE:BCR shares closed at $106.97 per share.